vladiwelt-shutterstock-com
vladiwelt / Shutterstock.com
12 May 2016PharmaTrevor Cook

Squatters’ rights: the problem with third party SPCs

Late in December 2015 the European Commission issued an invitation to tender inviting proposals for a study on the supplementary protection certificate (SPC) regulations, by which de facto patent term extension of up to five years can be secured in the EU for medicinal products and plant protection products once these receive a marketing authorisation (MA). The tender closed in February 2016 but it has been reported that the tender will be relaunched as none of the bids that were received met its requirements.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
14 October 2026   Efforts to bring a generic cyanide poisoning treatment to market have suffered a setback after a US judge rejected challenges to three patents and criticised the drugmaker’s interpretation of the treatment’s chemical composition.
Pharma
13 October 2026   Generic challengers have scored a win against the Danish company after an appeals board revoked a key patent covering the cardiovascular use of semaglutide. The decision strips away another layer of protection as generic manufacturers hunt down the semaglutide franchise.
Pharma
8 October 2026   Following ANDA litigation over Tafinlar earlier this year, the Swiss multinational has sued the generics maker over its proposed version of Mekinist, asserting patents that cover both the composition and treatment regimen.